CB1 receptor knockout mice are hyporesponsive to the behavior-stimulating actions of d-amphetamine: Role of mGlu5 receptors

European Neuropsychopharmacology

Volumn 19, Issue 3, 2009, Pages 196-204

  Tzavara, Eleni T ^a,b   Degroot, Aldemar ^a   Wade, Mark R ^a   Davis, Richard J ^a   Nomikos, George G ^a  

^a ELI LILLY AND COMPANY   (United States)

^b INSERM   (France)

Author keywords

CB1 receptor; d amphetamine; Dopamine; Locomotor activity; mGluR5; Microdialysis; MK 801

Indexed keywords

2 METHYL 6 (PHENYLETHYNYL)PYRIDINE; CANNABINOID 1 RECEPTOR; DEXAMPHETAMINE; DIZOCILPINE; METABOTROPIC RECEPTOR 5; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; RIMONABANT; SR 41716A; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DOPAMINE RELEASE; DRUG RECEPTOR BINDING; KNOCKOUT MOUSE; LOCOMOTION; MICRODIALYSIS; MOUSE; NEUROTRANSMISSION; NONHUMAN; NUCLEUS ACCUMBENS; PRIORITY JOURNAL; RECEPTOR BLOCKING; WILD TYPE;

AMPHETAMINE; ANALYSIS OF VARIANCE; ANIMALS; BEHAVIOR, ANIMAL; DIZOCILPINE MALEATE; DOPAMINE; DOPAMINE UPTAKE INHIBITORS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; HYPERKINESIS; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MICRODIALYSIS; MOTOR ACTIVITY; NUCLEUS ACCUMBENS; PIPERIDINES; PYRAZOLES; PYRIDINES; RECEPTOR, CANNABINOID, CB1; RECEPTORS, METABOTROPIC GLUTAMATE;

EID: 58949103818     PISSN: 0924977X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.euroneuro.2008.11.003     Document Type: Article

References (33)

1. Auclair N., Otani S., Soubrie P., and Crepel F. Cannabinoids modulate synaptic strength and plasticity at glutamatergic synapses of rat prefrontal cortex pyramidal neurons. J. Neurophysiol. 83 (2000) 3287-3293
2. Ballmaier M., Bortolato M., Rizzetti C., Zoli M., Gessa G., Heinz A., and Spano P. Cannabinoid receptor antagonists counteract sensorimotor gating deficits in the phencyclidine model of psychosis. Neuropsychopharmacology 32 (2007) 2098-2107
3. Corbillé A.G., Valjent E., Marsicano G., Ledent C., Lutz B., Hervé D., and Girault J.A. Role of cannabinoid type 1 receptors in locomotor activity and striatal signaling in response to psychostimulants. J. Neurosci. 27 (2007) 6937-6947
4. De Vries T.J., and Schoffelmeer A.N. Cannabinoid CB1 receptors control conditioned drug seeking. Trends Pharmacol. Sci. 26 (2005) 420-426
5. De Vries T.J., Shaham Y., Homberg J.R., Crombag H., Schuurman K., Dieben J., Vanderschuren L.J., and Schoffelmeer A.N. A cannabinoid mechanism in relapse to cocaine seeking. Nat. Med. 7 (2001) 1151-1154
6. Doherty J., and Dingledine R. Functional interactions between cannabinoid and metabotropic glutamate receptors in the central nervous system. Curr. Opin. Pharmacol. 3 (2003) 46-53
7. Franklin K.B.J., and Paxinos G. The Mouse Brain in Stereotaxic Coordinates (1997), Academic Press Inc, San Diego CA
8. Gerdeman G., and Lovinger D.M. CB1 cannabinoid receptor inhibits synaptic release of glutamate in rat dorsolateral striatum. J. Neurophysiol. 85 (2001) 468-471
9. Heusner C.L., Hnasko T.S., Szczypka M.S., Liu Y., During M.J., and Palmiter R.D. Viral restoration of dopamine to the nucleus accumbens is sufficient to induce a locomotor response to amphetamine. Brain Res. 980 (2003) 266-274
10. Homayoun H., Stefani M.R., Adams B.W., Tamagan G.D., and Moghaddam B. Functional interaction between NMDA and mGlu5 receptors: effects on working memory, instrumental learning, motor behaviors, and dopamine release. Neuropsychopharmacology 29 (2004) 1259-1269
11. Kegeles L.S., Abi-Dargham A., Zea-Ponce Y., Rodenhiser-Hill J., Mann J.J., Van Heertum R.L., Cooper T.B., Carlsson A., and Laruelle M. Modulation of amphetamine-induced striatal dopamine release by ketamine in humans: implications for schizophrenia. Biol. Psychiatry 48 (2000) 627-640
12. Kinney G.G., O'Brien J.A., Lemaire W., Burno M., Bickel D.J., Clements M.K., Chen T.B., Wisnoski D.D., Lindsley C.W., Tiller P.R., Smith S., Jacobson M.A., Sur C., Duggan M.E., Pettibone D.J., Conn P.J., and Williams Jr. D.L. A novel selective positive allosteric modulator of metabotropic glutamate receptor subtype 5 has in vivo activity and antipsychotic-like effects in rat behavioral models. J. Pharmacol. Exp. Ther. 313 (2005) 199-206
13. Lafourcade M., Elezgarai I., Mato S., Bakiri Y., Grandes P., and Manzoni O.J. Molecular components and functions of the endocannabinoid system in mouse prefrontal cortex. PLoS ONE 2 1 (2007) e709
14. Le Foll B., and Goldberg S.R. Cannabinoid CB1 receptor antagonists as promising new medications for drug dependence. J. Pharmacol. Exp. Ther. 312 (2005) 875-883
15. Madsen M.V., Peacock L., Werge T., and Andersen M.B. Effects of the cannabinoid CB1 receptor agonist CP55,940 and antagonist SR141716A on d-amphetamine-induced behaviours in Cebus monkeys. J. Psychopharmacol. 20 (2006) 622-628
16. Maldonado R., Valverde O., and Berrendero F. Involvement of the endocannabinoid system in drug addiction. Trends Neurosci. 29 (2006) 225-232
17. Martin R.S., Secchi R.L., Sung E., Lemaire M., Bonhaus D.W., Hedley L.R., and Lowe D.A. Effects of cannabinoid receptor ligands on psychosis-relevant behavior models in the rat. Psychopharmacology (Berl) 165 (2003) 128-135
18. Masserano J.M., Karoum F., and Wyatt R.J. SR141716A, a CB1 cannabinoid receptor antagonist, potentiates the locomotor stimulant effects of d-amphetamine and apomorphine. Behav. Pharmacol. 10 (1999) 429-432
19. Mato S., Chevaleyre V., Robbe D., Pazos A., Castillo P.E., and Manzoni O.J. A single in-vivo exposure to delta 9THC blocks endocannabinoid-mediated synaptic plasticity. Nature Neurosci. 7 (2004) 585-586
20. Meltzer H.Y., Arvanitis L., Bauer D., Rein W., and Meta-Trial Study Group. Placebo-controlled evaluation of four novel compounds for the treatment of schizophrenia and schizoaffective disorder. Am. J. Psychiatry 161 (2004) 975-984
21. Robbe D., Kopf M., Remaury A., Bockaert J., and Manzoni O.J. Endogenous cannabinoids mediate long-term synaptic depression in the nucleus accumbens. Proc. Natl. Acad. Sci. U S A. 99 (2002) 8384-8388
22. Patil S.T., Zhang L., Martenyi F., Lowe S.L., Jackson K.A., Andreev B.V., Avedisova A.S., Bardenstein L.M., Gurovich I.Y., Morozova M.A., Mosolov S.N., Neznanov N.G., Reznik A.M., Smulevich A.B., Tochilov V.A., Johnson B.G., Monn J.A., and Schoepp D.D. Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized Phase 2 clinical trial. Nat. Med. 13 (2007) 1102-1107
23. Poncelet M., Barnouin M.C., Breliere J.C., Le Fur G., and Soubrie P. Blockade of cannabinoid (CB1) receptors by SR141716 selectively antagonizes drug-induced reinstatement of exploratory behaviour in gerbils. Psychopharmacology 144 (1999) 144-150
24. Soria G., Mendizábal V., Touriño C., Robledo P., Ledent C., Parmentier M., Maldonado R., and Valverde O. Lack of CB1 cannabinoid receptor impairs cocaine self-administration. Neuropsychopharmacology 30 (2005) 1670-1680
25. Svenningsson P., Tzavara E.T., Carruthers R., Rachleff I., Wattler S., Nehls M., McKinzie D.L., Fienberg A.A., Nomikos G.G., and Greengard P. A common signaling pathway mediates actions of diverse classes of psychotomimetics. Science 302 (2003) 1412-1415
26. Tzavara E.T., Davis R.J., Perry K.W., Li X., Salhoff C., Bymaster F.P., Witkin J.M., and Nomikos G.G. The CB1 receptor antagonist SR141716A selectively increases monoaminergic neurotransmission in the medial prefrontal cortex: implications for therapeutic actions. Br. J. Pharmacol. 138 (2003) 544-553
27. Tzavara E.T., Bymaster F.P., Davis R.J., Wade M.R., Perry K.W., Wess J., McKinzie D.L., Felder C., and Nomikos G.G. M4 muscarinic receptors regulate the dynamics of cholinergic and dopaminergic neurotransmission: relevance to the pathophysiology and treatment of related CNS pathologies. FASEB J. 18 (2004) 1410-1412
28. Tzavara E.T., Li D.L., Moutsimilli L., Bisogno T., Di Marzo V., Phebus L.A., Nomikos G.G., and Giros B. Endocannabinoids activate transient receptor potential vanilloid 1 receptors to reduce hyperdopaminergia-related hyperactivity: therapeutic implications. Biol. Psychiatry 59 (2006) 508-515
29. Tzavara E.T., Wade M.R., Davis R.J., El Khoury M.-A., and Nomikos G.G. Role of metabotropic glutamate receptor 5 in the procholinergic effects of neuropsychotherapeutic compounds. Synapse 62 (2008) 940-943
30. Vlachou S., Stamatopoulou F., Nomikos G.G., and Panagis G. Enhancement of endocannabinoid neurotransmission through CB1 cannabinoid receptors counteracts the reinforcing and psychostimulant effects of cocaine. Int. J. Neuropsychopharmacol. 11 (2008) 905-923
31. Wolf M.E., Xue C.J., White F.J., and Dahlin S.L. MK-801 does not prevent acute stimulatory effects of amphetamine or cocaine on locomotor activity or extracellular dopamine levels in rat nucleus accumbens. Brain Res. 666 (1994) 223-231
32. Xi Z.X., Gilbert J.G., Peng X.Q., Pak A.C., Li X., and Gardner E.L. Cannabinoid CB1 receptor antagonist AM251 inhibits cocaine-primed relapse in rats: role of glutamate in the nucleus accumbens. J. Neurosci. 26 (2006) 8531-8536
33. Zimmer A., Zimmer A.M., Hohmann A.G., Herkenham M., and Bonner T.I. Increased mortality, hypoactivity, and hypoalgesia in cannabinoid CB1 receptor knockout mice. Proc. Natl. Acad. Sci. U S A. 96 (1999) 5780-5785